| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2020 | PRGO Perrigo Co Plc | Janish Ronald Craig61 | EVP, Global Op. &Supply Chain | Sell | 2,595 | $51.90 | $134,671.32 | -12.9% | |
| May 7, 2020 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 8,682 | $105.44 | $915,454.39 | -7.7% | |
| May 7, 2020 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 50,000 | $14.63 | $731,265.00 | -6.2% | |
| May 7, 2020 | MRK Merck & Co., Inc. | Weeks Wendell P62 | Director | Sell | 5,000 | $76.02 | $380,103.50 | -98.0% | |
| May 6, 2020 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Senior Vice President | Sell | 37,000 | $4.50 | $166,430.00 | -8.2% | |
| May 5, 2020 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 8,375 | $80.19 | $671,628.94 | -51.1% | |
| May 5, 2020 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 25,000 | $14.06 | $351,425.00 | -11.0% | |
| May 5, 2020 | CVSI Cv Sciences, Inc. | Mona Michael Joseph Jr | 10% Owner | Sell | 1,409,000 | $0.67 | $938,329.05 | -3.6% | |
| May 1, 2020 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $16.66 | $8,328.80 | -0.7% | |
| May 1, 2020 | TLRY Tilray Brands, Inc. | Auerbach Michael | Director | Sell | 220,711 | $7.38 | $1,629,222.39 | -19.7% | |
| May 1, 2020 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 1,179 | $127.44 | $150,251.76 | -6.7% | |
| Apr 30, 2020 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 40,000 | $74.13 | $2,965,000.00 | -1.6% | |
| Apr 29, 2020 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Sell | 40,000 | $4.50 | $180,000.00 | -3.8% | |
| Apr 28, 2020 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,741 | $102.49 | $178,435.09 | -22.6% | |
| Apr 28, 2020 | NBIX Neurocrine Biosciences Inc | Sherwin Stephen A | Director | Sell | 17,687 | $99.39 | $1,757,965.76 | -37.2% | |
| Apr 28, 2020 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | SVP And General Counsel | Sell | 7,198 | $13.13 | $94,529.17 | -5.1% | |
| Apr 27, 2020 | AYTU Aytu Biopharma, Inc | Armistice Capital, LLC56 | Director | Sell | 5,108,921 | $1.82 | $9,298,236.22 | -100% | |
| Apr 27, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 12,663 | $163.60 | $2,071,714.92 | - | |
| Apr 27, 2020 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 7,893 | $78.00 | $615,654.00 | -32.5% | |
| Apr 27, 2020 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 30,033 | $13.77 | $413,407.25 | -4.5% | |
| Apr 27, 2020 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Sell | 80,000 | $3.85 | $308,000.00 | -4.0% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,934 | $99.41 | $192,258.17 | -1.7% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,934 | $99.52 | $192,466.85 | -20.1% | |
| Apr 24, 2020 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 1,934 | $99.46 | $192,351.19 | -1.3% | |
| Apr 24, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $162.47 | $35,743,217.60 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.